Drug Trial Radar · NCT06106009
A Study to Learn How Different Amounts of the Study Medicine Called PF-07976016 Are Tolerated and Act in The Body in Healthy Adults
Last checked: Nov 19, 2026Latest source record: Sep 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
117
Actual
Start
Oct 27, 2023
Primary completion
Aug 19, 2024
Study completion Aug 19, 2024
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Oct 30, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this clinical trial is to learn if the study medicine (called PF-07976016) is safe and how it goes in and out of the body in healthy people. The study may also explore if PF-07976016 has the potential to interact with another medicine called midazolam. In addition, the study may explore how PF-07976016 goes into the body of people who have obesity.
Conditions
- Healthy
Interventions
PF-07976016Drug
Oral solution, oral suspension or solid oral formulation(s)
PlaceboDrug
Oral solution, oral suspension or solid oral formulation(s)
MidazolamDrug
Midazolam oral solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Number of Participants With Treatment Emergent Adverse Events Following Single DosesTime frame: Day 1 up to approximately Day 36
- Part A: Number of Participants With Clinical Laboratory Abnormalities Following Single DosesTime frame: Day 1 up to approximately Day 36
- Part A: Number of Participants With Clinically Significant Change in Baseline Vital Signs Following Single DosesTime frame: Day 1 up to approximately Day 36
- Part A: Number of Participants With Clinically Significant Change from Baseline in Electrocardiogram Findings Following Single DosesTime frame: Day 1 up to approximately Day 36
- Part B, Parts C and D, if conducted: Number of Participants With Treatment Emergent Adverse Events Following Multiple DosesTime frame: Day 1 up to approximately Day 49
- Part B, Parts C and D, if conducted: Number of Participants With Clinical Laboratory Abnormalities Following Multiple DosesTime frame: Day 1 up to approximately Day 49
- Part B, Parts C and D, if conducted: Number of Participants With Clinically Significant Change in Baseline Vital Signs Following Multiple DosesTime frame: Day 1 up to approximately Day 49
- Part B, Parts C and D, if conducted: Number of Participants With Clinically Significant Change from Baseline in Electrocardiogram Findings Following Multiple DosesTime frame: Day 1 up to approximately Day 49
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pfizer Clinical Research Unit - New Haven
New Haven, Connecticut
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.